95°F
Sponsored by

Cancer Killing Combo: New Lung Cancer Treatment

<br mce_bogus="1">


It's the leading cause of cancer deaths in both men and women, higher than colon, breast and prostate cancer.

Each year, lung cancer strikes more than 220,000 people.

It will kill 160,000, but adding something to chemotherapy could help beat the disease.

Kimberly Thomas says, "It keeps my mind at peace cause I know that I'm not alone."

Kimberly Thomas's "We got this" bracelet is a symbol of all the support she's gotten since her diagnosis.

Thomas: "I was devastated"

Kimberly has small cell carcinoma, a very aggressive form of lung cancer, but something new could help her overcome it.

University of Tennessee Medical Center's Doctor Wahid Hanna is helping investigate how adding immune-boosting antibodies to chemotherapy drugs could help patients like Kim.

Dr. Hanna says, "If you have a cell that is requiring oxygen and you interfere with the nutrition, you interfere with the way it gets the cells to grow, that's it it'll die."

The antibody attaches itself to cancer cells, making the cancer vulnerable to being destroyed by a patient's own immune system. 

After six rounds of the chemotherapy combined with the antibody...

Thomas: "It makes me feel ecstatic that there's hope."

Kimberly and her daughter Vicotoria hope the tumor will eventually disappear so they can enjoy many more miles of quality time together.

Victoria Marlow says, "We have definitely gotten closer and, um, it's kind of a blessing."

After patients complete the combination treatment, they can choose to continue taking the antibody without the chemotherapy.

Patients from around the World are being recruited to take part in the phase two study.

Go to---> http://clinicaltrials.gov/ct2/show/study/NCT01237678?term=small+cell+lung+ca&recr=Open&rank=6&show_locs=Y#locn> for enrollment information.

Page: [[$index + 1]]
comments powered by Disqus

Poll

[[viewModel.Question]]

[[result.OptionText]] [[calculateVotePercent(result)]]%
[[settings.DelayedResultsMessage]]
Poll sponsored by